BC Extra | Nov 7, 2015
Clinical News

Alzheon: Data justify pursuit of homozygous AD patients

Alzheon Inc. (Framingham, Mass.) said tramiprosate improved cognition in mild to moderate Alzheimer's disease patients homozygous for apolipoprotein E epsilon 4 ( APOE4 ) in a subgroup analysis of two earlier Phase III studies. Alzheon said the...
BC Extra | Apr 8, 2015
Financial News

Alzheon raises $10M in series A round

Alzheon Inc. (Framingham, Mass.) raised $10 million in a series A round led by new investor Ally Bridge Group. Undisclosed new and existing investors also participated. CEO Martin Tolar told BioCentury the company hopes to...
BC Innovations | Mar 20, 2014
Tools & Techniques

Plasma lipids: harbingers of AD?

A panel of plasma lipids could represent a new diagnostic tool for identifying patients likely to develop Alzheimer's disease before symptoms appear, according to new clinical findings from a team of U.S. researchers. 1 Although...
BioCentury | Nov 25, 2013
Emerging Company Profile

Alzheon: Once more, with APOE4

Alzheon Inc. is the latest company to take a stab at treating Alzheimer's disease with a small molecule inhibitor of beta amyloid aggregation. The company has an improved version of a previously unsuccessful compound and...
BC Week In Review | Apr 9, 2012
Company News

Bellus Health, Pharmascience deal

Generics company Pharmascience will pay C$17.3 million ($17.4 million) to recapitalize Bellus Health into a new public company. Pharmascience will provide C$8.2 million ($8.2 million) in non-dilutive capital to Bellus and will make a C$9.1...
BC Extra | Apr 6, 2012
Company News

Pharmascience to pay $17.4M to recapitalize Bellus

Generics company Pharmascience Inc. (Montreal, Quebec) will pay C$17.3 million ($17.4 million) to recapitalize Bellus Health Inc. (TSX:BLU) into a new public company. Pharmascience will provide C$8.2 million ($8.2 million) in non-dilutive capital to Bellus...
BC Innovations | Mar 8, 2012
Cover Story

Working on the brain gang(lioside)

Canadian researchers have found that injecting ganglioside GM1 , a naturally occurring lipid, into the brains of mice with Huntington's disease improves motor function and slows disease progression. 1 The team is in talks with an...
BC Week In Review | Sep 26, 2011
Company News

Thrasos Inc. management update

Thrasos Inc. , Montreal, Quebec   Business: Renal   Hired: Andreas Orfanos as CMO, formerly EVP of strategic planning and scientific affairs at Bellus Health Inc. (formerly Neurochem Inc. )  ...
BC Innovations | Jan 6, 2011
Targets & Mechanisms

More mileage out of myelin

A team led by U.K. researchers has shown that retinoid X receptor agonists can enhance remyelination of demyelinated axons in rodents by increasing the differentiation of oligodendrocyte precursor cells into oligodendrocytes. 1 This remyelination activity...
BC Innovations | Sep 2, 2010
Cover Story

Kinase race in PD

It's not every day that academic drug discovery outpaces a company, but a team at The Johns Hopkins University thinks it has done just that by providing the first in vivo proof of concept that...
Items per page:
1 - 10 of 220
BC Extra | Nov 7, 2015
Clinical News

Alzheon: Data justify pursuit of homozygous AD patients

Alzheon Inc. (Framingham, Mass.) said tramiprosate improved cognition in mild to moderate Alzheimer's disease patients homozygous for apolipoprotein E epsilon 4 ( APOE4 ) in a subgroup analysis of two earlier Phase III studies. Alzheon said the...
BC Extra | Apr 8, 2015
Financial News

Alzheon raises $10M in series A round

Alzheon Inc. (Framingham, Mass.) raised $10 million in a series A round led by new investor Ally Bridge Group. Undisclosed new and existing investors also participated. CEO Martin Tolar told BioCentury the company hopes to...
BC Innovations | Mar 20, 2014
Tools & Techniques

Plasma lipids: harbingers of AD?

A panel of plasma lipids could represent a new diagnostic tool for identifying patients likely to develop Alzheimer's disease before symptoms appear, according to new clinical findings from a team of U.S. researchers. 1 Although...
BioCentury | Nov 25, 2013
Emerging Company Profile

Alzheon: Once more, with APOE4

Alzheon Inc. is the latest company to take a stab at treating Alzheimer's disease with a small molecule inhibitor of beta amyloid aggregation. The company has an improved version of a previously unsuccessful compound and...
BC Week In Review | Apr 9, 2012
Company News

Bellus Health, Pharmascience deal

Generics company Pharmascience will pay C$17.3 million ($17.4 million) to recapitalize Bellus Health into a new public company. Pharmascience will provide C$8.2 million ($8.2 million) in non-dilutive capital to Bellus and will make a C$9.1...
BC Extra | Apr 6, 2012
Company News

Pharmascience to pay $17.4M to recapitalize Bellus

Generics company Pharmascience Inc. (Montreal, Quebec) will pay C$17.3 million ($17.4 million) to recapitalize Bellus Health Inc. (TSX:BLU) into a new public company. Pharmascience will provide C$8.2 million ($8.2 million) in non-dilutive capital to Bellus...
BC Innovations | Mar 8, 2012
Cover Story

Working on the brain gang(lioside)

Canadian researchers have found that injecting ganglioside GM1 , a naturally occurring lipid, into the brains of mice with Huntington's disease improves motor function and slows disease progression. 1 The team is in talks with an...
BC Week In Review | Sep 26, 2011
Company News

Thrasos Inc. management update

Thrasos Inc. , Montreal, Quebec   Business: Renal   Hired: Andreas Orfanos as CMO, formerly EVP of strategic planning and scientific affairs at Bellus Health Inc. (formerly Neurochem Inc. )  ...
BC Innovations | Jan 6, 2011
Targets & Mechanisms

More mileage out of myelin

A team led by U.K. researchers has shown that retinoid X receptor agonists can enhance remyelination of demyelinated axons in rodents by increasing the differentiation of oligodendrocyte precursor cells into oligodendrocytes. 1 This remyelination activity...
BC Innovations | Sep 2, 2010
Cover Story

Kinase race in PD

It's not every day that academic drug discovery outpaces a company, but a team at The Johns Hopkins University thinks it has done just that by providing the first in vivo proof of concept that...
Items per page:
1 - 10 of 220